These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 28666858)
21. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release. Cosi C; Carilla-Durand E; Assié MB; Ormiere AM; Maraval M; Leduc N; Newman-Tancredi A Eur J Pharmacol; 2006 Mar; 535(1-3):135-44. PubMed ID: 16554049 [TBL] [Abstract][Full Text] [Related]
22. Dopamine receptor heteromers: biasing antipsychotics. Sahlholm K; Valle-León M; Fernández-Dueñas V; Ciruela F Future Med Chem; 2018 Dec; 10(23):2675-2677. PubMed ID: 30518245 [No Abstract] [Full Text] [Related]
23. Chemical synthesis, microbial transformation and biological evaluation of tetrahydroprotoberberines as dopamine D1/D2 receptor ligands. Ge H; Zhang Y; Yang Z; Qiang K; Chen C; Sun L; Chen M; Zhang J Bioorg Med Chem; 2019 May; 27(10):2100-2111. PubMed ID: 30981605 [TBL] [Abstract][Full Text] [Related]
24. Distinct cortical and striatal actions of a β-arrestin-biased dopamine D2 receptor ligand reveal unique antipsychotic-like properties. Urs NM; Gee SM; Pack TF; McCorvy JD; Evron T; Snyder JC; Yang X; Rodriguiz RM; Borrelli E; Wetsel WC; Jin J; Roth BL; O'Donnell P; Caron MG Proc Natl Acad Sci U S A; 2016 Dec; 113(50):E8178-E8186. PubMed ID: 27911814 [TBL] [Abstract][Full Text] [Related]
25. Synthesis and characterization of selective dopamine D2 receptor antagonists. Vangveravong S; McElveen E; Taylor M; Xu J; Tu Z; Luedtke RR; Mach RH Bioorg Med Chem; 2006 Feb; 14(3):815-25. PubMed ID: 16288878 [TBL] [Abstract][Full Text] [Related]
26. New arylpiperazinylalkyl derivatives of 8-alkoxy-purine-2,6-dione and dihydro[1,3]oxazolo[2,3-f]purinedione targeting the serotonin 5-HT1A /5-HT2A /5-HT7 and dopamine D2 receptors. Chłoń-Rzepa G; Zagórska A; Bucki A; Kołaczkowski M; Pawłowski M; Satała G; Bojarski AJ; Partyka A; Wesołowska A; Pękala E; Słoczyńska K Arch Pharm (Weinheim); 2015 Apr; 348(4):242-53. PubMed ID: 25773907 [TBL] [Abstract][Full Text] [Related]
27. Haloperidol bound D Fan L; Tan L; Chen Z; Qi J; Nie F; Luo Z; Cheng J; Wang S Nat Commun; 2020 Feb; 11(1):1074. PubMed ID: 32103023 [TBL] [Abstract][Full Text] [Related]
28. Design and synthesis of novel N-sulfonyl-2-indoles that behave as 5-HT Saavedra OM; Karila D; Brossard D; Rojas A; Dupuis D; Gohier A; Mannoury la Cour C; Millan MJ; Ortuno JC; Hanessian S Bioorg Med Chem; 2017 Jan; 25(1):38-52. PubMed ID: 28029458 [TBL] [Abstract][Full Text] [Related]
29. New dual ligands for the D Zaręba P; Jaśkowska J; Śliwa P; Satała G Bioorg Med Chem Lett; 2019 Aug; 29(16):2236-2242. PubMed ID: 31253532 [TBL] [Abstract][Full Text] [Related]
30. Design, synthesis, and evaluation of metabolism-based analogues of haloperidol incapable of forming MPP+-like species. Lyles-Eggleston M; Altundas R; Xia J; Sikazwe DM; Fan P; Yang Q; Li S; Zhang W; Zhu X; Schmidt AW; Vanase-Frawley M; Shrihkande A; Villalobos A; Borne RF; Ablordeppey SY J Med Chem; 2004 Jan; 47(3):497-508. PubMed ID: 14736232 [TBL] [Abstract][Full Text] [Related]
31. A single glycine in extracellular loop 1 is the critical determinant for pharmacological specificity of dopamine D2 and D3 receptors. Michino M; Donthamsetti P; Beuming T; Banala A; Duan L; Roux T; Han Y; Trinquet E; Newman AH; Javitch JA; Shi L Mol Pharmacol; 2013 Dec; 84(6):854-64. PubMed ID: 24061855 [TBL] [Abstract][Full Text] [Related]
32. Docking Screens of Noncovalent Interaction Motifs of the Human Subtype-D2 Receptor-75 Schizophrenia Antipsychotic Complexes with Physicochemical Appraisal of Antipsychotics. Amani P; Habibpour R; Karami L; Hofmann A ACS Chem Neurosci; 2021 Jun; 12(12):2218-2232. PubMed ID: 34061513 [TBL] [Abstract][Full Text] [Related]
33. Ligand-directed bias of G protein signaling at the dopamine D Von Moo E; Harpsøe K; Hauser AS; Masuho I; Bräuner-Osborne H; Gloriam DE; Martemyanov KA Cell Chem Biol; 2022 Feb; 29(2):226-238.e4. PubMed ID: 34302750 [TBL] [Abstract][Full Text] [Related]
34. Antagonism of Dopamine Receptor 2 Long Affects Cannabinoid Receptor 1 Signaling in a Cell Culture Model of Striatal Medium Spiny Projection Neurons. Bagher AM; Laprairie RB; Kelly ME; Denovan-Wright EM Mol Pharmacol; 2016 Jun; 89(6):652-66. PubMed ID: 27053685 [TBL] [Abstract][Full Text] [Related]
35. Examining the Effects of Sodium Ions on the Binding of Antagonists to Dopamine D2 and D3 Receptors. Newton CL; Wood MD; Strange PG PLoS One; 2016; 11(7):e0158808. PubMed ID: 27379794 [TBL] [Abstract][Full Text] [Related]
36. Structure of the dopamine D Im D; Inoue A; Fujiwara T; Nakane T; Yamanaka Y; Uemura T; Mori C; Shiimura Y; Kimura KT; Asada H; Nomura N; Tanaka T; Yamashita A; Nango E; Tono K; Kadji FMN; Aoki J; Iwata S; Shimamura T Nat Commun; 2020 Dec; 11(1):6442. PubMed ID: 33353947 [TBL] [Abstract][Full Text] [Related]
37. Synthesis and binding profile of haloperidol-based bivalent ligands targeting dopamine D(2)-like receptors. Salama I; Löber S; Hübner H; Gmeiner P Bioorg Med Chem Lett; 2014 Aug; 24(16):3753-6. PubMed ID: 25047579 [TBL] [Abstract][Full Text] [Related]
38. The Dopamine D2 Receptor Contributes to the Spheroid Formation Behavior of U87 Glioblastoma Cells. Weissenrieder JS; Reed JL; Green MV; Moldovan GL; Koubek EJ; Neighbors JD; Hohl RJ Pharmacology; 2020; 105(1-2):19-27. PubMed ID: 31645049 [TBL] [Abstract][Full Text] [Related]
39. Comparison between olanzapine and haloperidol on procedural learning and the relationship with striatal D2 receptor occupancy in schizophrenia. Paquet F; Soucy JP; Stip E; Lévesque M; Elie A; Bédard MA J Neuropsychiatry Clin Neurosci; 2004; 16(1):47-56. PubMed ID: 14990759 [TBL] [Abstract][Full Text] [Related]
40. SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist. I: Neurochemical and electrophysiological profile. Claustre Y; Peretti DD; Brun P; Gueudet C; Allouard N; Alonso R; Lourdelet J; Oblin A; Damoiseau G; Françon D; Suaud-Chagny MF; Steinberg R; Sevrin M; Schoemaker H; George P; Soubrié P; Scatton B Neuropsychopharmacology; 2003 Dec; 28(12):2064-76. PubMed ID: 12902994 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]